RandomPhIIStereotacticAblativeRadiationTherMetUnresecRenalCellCaReceivImmunotherapy
Shera Beth Feinstein
- OPEN TO ACCRUAL
trials found matching your search:
Displaying 20 of 290 Results
Phase , Multiple Sclerosis, ofatumumab, INT-Drug
Michael Sy
- RRI SIGNOFF
Efficacy & safety of extended TARPEYO treatment >9 months in adult patients w primary IgA nephropath
Ramy Hanna
- OPEN TO ACCRUAL
PhIIIbRandoControlTrialNadofarageneFiradenovecVSObservSubjW/IntermedRiskNonMuscleInvasiveBladderCa
Edward Uchio
- OPEN TO ACCRUAL
A Phase 2a, Open-Label Pilot Study to Evaluate
Amin Sabet
- OPEN TO ACCRUAL
A Phase II Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma
Ling Gao
- OPEN TO ACCRUAL
LoTamRandomPhIII LowDosTamoxifenSelectPa w/MolecularLowRiskEarlyStageBreastCa
Ritesh Parajuli
- OPEN TO ACCRUAL
RepurposingRiluzoleAugmentBrainDerivedNeuropathFactorLevel&CogFunc BreastCaPa ExpCa-Related CogImpai
Alexandre Chan
- OPEN TO ACCRUAL
PhII Consolidation Therapy for Relapsed/Refractory LargeB-CellLympoma or GradeIIIBFollicularLymphoma
Elizabeth A Brem
- OPEN TO ACCRUAL
Phase 1 Trial of Iadademstat in Combination with Venetoclax and Azacitidine
Kiran Naqvi
- OPEN TO ACCRUAL
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax after Allogen Hemato Cell Transpla
Piyanuch Kongtim
- OPEN TO ACCRUAL
Vitaccess Real MG Registry
Ali Habib
- OPEN TO ACCRUAL
Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
Anand Ganesan
- OPEN TO ACCRUAL
Response Adapted Neoadjuvant Therapy in Gastric Cancer (RANT-GC) Trial
Farshid Dayyani
- OPEN TO ACCRUAL
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents with Sickle Cell Disease
Zahra Pakbaz
- OPEN TO ACCRUAL
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
Jay Shah
- OPEN TO ACCRUAL
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
Ramy Hanna
- OPEN TO ACCRUAL
Personalized fluid administration using an assisted fluid management system
Sean Coeckelenbergh
- OPEN TO ACCRUAL
RadThe forHighriskAsymptomaticBoneMets PragmaticMulticentRandPhIIIClinicalTrial(PREEMPT)
Jeremy Harris
- OPEN TO ACCRUAL
Ph I CB-010 CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Ptsw/ R/R Non-Hodgkin Lymphoma
Susan O'Brien
- OPEN TO ACCRUAL